
    
      This experimental use umbilical cord mesenchymal stem cells in treatment of decompensated
      hepatitis B cirrhosis to evaluate its safety and efficacy,

      This experimental is mainly aimed at people aged 18-60 years old, regardless of gender and
      with body mass index (BMI) between 19-25kg/m2 (including boundary value). It was decided into
      treatment group and control group to evaluate the effectiveness and safety of mesenchymal
      stem cells by peripheral intravenous injection.
    
  